Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

1. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21;377(12):1119–1131.
2. Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018 Oct 16;169(8):535–542.